Table 3.
Author (Year) | Phase | N | Dose of Remimazolam | Age (Years) | Primary Endpoint | Comparator | Co-Treatment | Location (s) | Results |
---|---|---|---|---|---|---|---|---|---|
Rex et al 201841 | III | 461 | 5.0 mg plus 2.5 top-ups | 18–74 | Efficacy and safety of remimazolam in patients undergoing colonoscopy | Midazolam [1.75 mg plus 0.5 mg (≥60 years) or 1.0 mg (<60 years) top-ups] | Fentanyl (75 μg) | USA | Patients in remimazolam group had Procedural success rate, faster mean procedure time and recovery time, less needed of fentanyl, less incidence of hypotension |
Liu et al 202142 | III | 260 | 0.15mg/kg plus 0.075 mg/kg top-ups | 65–75 | Efficacy and safety of remimazolam in elderly outpatients undergoing colonoscopy | Etomidate-Propofol (0.1 mL/kg plus 0.05 mL/kg top-ups) | Fentanyl (0.15 mg/kg plus 0.5 mg/kg top-ups, the maximum dose of 150 μg) | China | The procedure success rate in remimazolam group was non-inferior to etomidate-propofol group (96.52% vs 100.00%; difference in rate −3.48%, 95% CI −6.81% to −0.15%), and has a higher safety for elderly patients |
Rex et al 202143 | III | 79 | 2.5–5.0 mg plus 1.25–2.5 mg top-ups | 42–84 | Safety and efficacy of remimazolam in ASA class III/IV patients undergoing colonoscopy | Midazolam (1.0 mg plus 0.5 mg top-ups) | Fentanyl (50 μg, top up doses of 25 μg, the maximum dose of 200 μg) | USA | Procedure success for patients treated with remimazolam, placebo, midazolam was 87.1%, 0%, 13.3%, the shorter time to sedation and recovery in remimazolam group, and no serious AEs were reported. it can be efficacy and safety for sedation in ASA III/IV patients |
Yao et al 202244 | III | 132 | 0.2 mg/kg plus 6 mg top-ups | 18–65 | Discharge readiness after remimazolam versus propofol for colonoscopy | Propofol (1 mg/kg plus 30 mg top-ups) | Sufentanil (5 mg) | China | Remimazolam provided a similar sedative efficacy and safer profile in patients undergoing colonoscopy, compared with propofol |
Abbreviations: N, number of subjects; N/A, not available/applicable.